STOCK TITAN
  1. Home
  2. Sec-filings
  3. TLSIW
  4. [8-K] TriSalus Life Sciences, Inc. Reports Material Event

TriSalus Life Sciences (TLSI) taps Richard Marshall, M.D., as Chief Medical Officer

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. appointed Richard Marshall, M.D. as Chief Medical Officer, effective June 29, 2026. He will move into this full-time role from his current position as Medical Director and will lead medical strategy, clinical development and evidence generation across the company’s oncology programs.

Under his offer letter, Dr. Marshall will receive an annual base salary of $525,000, a $250,000 sign-on bonus, and will be eligible for an annual bonus of up to 50% of base salary based on Board-determined goals. Following his start date, the Board will be asked to grant him 120,000 stock options and 60,000 restricted stock units, with further annual equity grants possible under the Equity Incentive Plan.

The accompanying press release highlights Dr. Marshall’s background in interventional oncology and his role in supporting TriSalus’ Pressure-Enabled Drug Delivery platform, TriNav devices and investigational immunotherapy nelitolimod as the company advances treatments for solid tumors.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Chief Medical Officer base salary $525,000 per year Annual base salary for Dr. Marshall under offer letter
Sign-on bonus $250,000 One-time sign-on bonus for new Chief Medical Officer
Target annual bonus opportunity Up to 50% of base salary Performance-based annual bonus opportunity for Dr. Marshall
Stock options grant 120,000 stock options Equity award to be recommended to the Board after start date
Restricted stock units grant 60,000 RSUs Restricted stock units to be recommended following employment start
Effective date as CMO June 29, 2026 Date Dr. Marshall becomes Chief Medical Officer full-time
Equity Incentive Plan financial
"In addition, Dr. Marshall will be eligible for an annual equity grant under the Company’s Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
restricted stock units financial
"an equity award be granted to Dr. Marshall for 120,000 stock options and 60,000 restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Pressure-Enabled Drug Delivery technical
"our TriNav product suite and proprietary Pressure-Enabled Drug Delivery (“PEDD”) platform across a broad range of indications"
A method of getting medicine into the body by applying controlled pressure—using a small pump, device or pressurized system—to push a drug through skin or into targeted tissue rather than relying on swallowing or passive absorption. Investors care because this approach can make treatments faster, more reliable, or usable for drugs that otherwise can’t be given orally, creating potential clinical advantages, new product lines, regulatory hurdles, manufacturing needs, and patent value.
nelitolimod medical
"its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist"
forward-looking statements regulatory
"Statements made in this press release regarding matters that are not historical facts are “forward-looking statements”"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Understanding 8-K Material Events →
0001826667FALSE00018266672026-04-012026-04-010001826667us-gaap:CommonStockMember2026-04-012026-04-010001826667us-gaap:WarrantMember2026-04-012026-04-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 1, 2026
TRISALUS LIFE SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-39813
85-3009869
(State or other jurisdiction of
incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
6272 W 91st Ave, Westminster, Colorado
80031
(Address of principal executive office)(Zip Code)
(888) 321-5212
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.0001 par value
TLSI
Nasdaq Global Market
Warrants, each whole warrant exercisable for one share of registrant's common stock at an exercise price of $11.50 per share
TLSIW
Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 1, 2026, TriSalus Life Sciences, Inc. (the “Company”) entered into an offer letter with Dr. Richard Marshall for the position of Chief Medical Officer. Dr. Marshall’s employment is expected to start on June 29, 2026 with an annual base salary of $525,000 and a sign on bonus of $250,000. Dr. Marshall will also be eligible for an annual bonus of up to 50% of his annual base salary based on the achievement of financial goals and milestones as determined by the Board of Directors (the “Board”). Following the start of his employment, the Company will recommend to the Board an equity award be granted to Dr. Marshall for 120,000 stock options and 60,000 restricted stock units. In addition, Dr. Marshall will be eligible for an annual equity grant under the Company’s Equity Incentive Plan, subject to Board approval.
There have been no related party transactions between Dr. Marshall and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Item 7.01
Regulation FD Disclosure.
On April 7, 2026, the Company issued a press release announcing Dr. Marshall’s appointment as Chief Medical Officer of the Company, effective June 29, 2026. A copy of our press release, dated April 7, 2026, announcing Dr. Marshall’s appointment is attached hereto as Exhibit 99.1.
The information under this Item 7.01, including Exhibit 99.1, will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and it will not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits:
Exhibit NumberDescription
99.1
Press Release dated April 7, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 7, 2026
TriSalus Life Sciences, Inc.
By:/s/ David Patience
Name:David Patience
Title:Chief Financial Officer


TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer

WESTMINSTER, Colo. — April 7, 2026 — TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of Richard Marshall, M.D., as Chief Medical Officer on a full-time basis, effective June 29, 2026. Dr. Marshall will transition into the role from his current position as Medical Director, a role he has held since January 2025. In his new capacity, he will lead the Company’s medical strategy and provide clinical leadership across development, evidence generation and broader strategic initiatives.

"Dr. Marshall brings a rare combination of frontline clinical insight and deep interventional oncology expertise that is uniquely aligned with our mission. Since joining TriSalus as Medical Director, he has been an invaluable clinical voice in driving the expansion of our TriNav product suite and proprietary Pressure-Enabled Drug Delivery (“PEDD”) platform across a broad range of indications beyond the liver.” said Mary Szela, President and Chief Executive Officer of TriSalus. “As we continue to see strong physician engagement, utilization and interest in the PEDD platform, Dr. Marshall's appointment as Chief Medical Officer positions us to accelerate the advancement of our clinical and economic advantages data and deliver meaningful impact for patients."

Dr. Marshall is an interventional radiologist with extensive experience spanning interventional oncology, hepatobiliary interventions and trauma care. After graduating from Tulane University School of Medicine, he completed his diagnostic radiology residency at Ochsner Clinic Foundation, where he served as Chief Resident, followed by fellowship training in interventional radiology and interventional oncology at Weill Cornell University and Memorial Sloan Kettering Cancer Center in New York. He joined the faculty at Louisiana State University Health Sciences Center and then Tulane University, both in New Orleans.

During his time at LSU Health Sciences Center, Dr. Marshall developed Louisiana’s first Interventional Radiology Residency and led a high-volume clinical practice focused on interventional oncology, hepatobiliary interventions and trauma care. Since 2021, he has also served at Tulane University School of Medicine, where he has remained active in medical student and resident education. His clinical experience has included care for patients undergoing organ transplantation, pediatric interventions, embolization for thyroid disease and uterine fibroids, musculoskeletal pain palliation, venous interventions and palliative care.

“I am honored to step into the Chief Medical Officer role at TriSalus at this important time for the Company,” said Dr. Marshall. “TriSalus is working to address significant challenges in the treatment of liver and pancreatic tumors to provide meaningful benefits to patients. I look forward to helping advance the Company’s medical and clinical efforts as we continue to build on the potential of the PEDD approach and support better and safer patient outcomes.”

Dr. Marshall’s appointment reflects TriSalus’ continued focus on strengthening its leadership team as the Company advances its PEDD platform, which combines its drug delivery technology with therapeutic development efforts aimed at improving outcomes for patients with solid tumors.
-1-




About TriSalus Life Sciences
TriSalus Life Sciences® is an oncology focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s three FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav® Infusion System and TriNav Infusion System LV for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via the PEDD technology may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by the PEDD technology are commonly present as well. The Company is in the final stages of data completion for a number of phase 1 clinical trials and will begin exploring partnership opportunities for development.
Forward Looking Statements
Statements made in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding fourth quarter 2025 and full year 2025 financial results and 2026 financial outlook and future profitability, cash flows, and the Company’s ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include the risk that the Company will not become profitable on its expected timeline, if at all, the risk that the reported financial results will differ from the estimates provided in this press release, risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company’s clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company’s ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, , changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, made in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such
-2-




forward‐looking statements. Such statements include, but are not limited to, statements regarding the benefits and potential benefits of the Company’s PEDD drug delivery technology, TriNav® system and nelitolimod investigational immunotherapy, and the Company’s ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company’s clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company’s ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, the risk that the Company will not become profitable on its expected timeline, if at all, the risk that the reported financial results will differ from the estimates provided in this press release, changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, and other risks described in the Company’s filings with the Securities and Exchange Commission under the heading “Risk Factors.” All forward‐looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law.

Contacts
For Media Inquiries:
Jeremy Feffer, Managing Director
LifeSci Advisors
212.915.2568
jfeffer@lifesciadvisors.com

For Investor Inquiries:
David Patience
Chief Financial Officer
investor.relations@trisaluslifesci.com
-3-



Source: View Original Filing on SEC EDGAR

FAQ

What did TriSalus Life Sciences (TLSI) announce in this 8-K filing?

TriSalus Life Sciences announced the appointment of Richard Marshall, M.D., as Chief Medical Officer, effective June 29, 2026. He will lead medical strategy and clinical development as the company advances its Pressure-Enabled Drug Delivery platform and investigational immunotherapy programs for solid tumors.

What is the compensation package for TriSalus’ new Chief Medical Officer?

Dr. Marshall will receive a $525,000 annual base salary and a $250,000 sign-on bonus. He is also eligible for an annual bonus up to 50% of base salary and proposed equity awards of 120,000 stock options and 60,000 restricted stock units, plus future annual equity grants.

What equity awards will Richard Marshall receive from TriSalus Life Sciences?

Following his start date, TriSalus plans to recommend the Board grant Dr. Marshall 120,000 stock options and 60,000 restricted stock units. He will also be eligible for ongoing annual equity grants under the company’s Equity Incentive Plan, aligning his incentives with longer-term shareholder interests.

What is TriSalus Life Sciences’ PEDD drug delivery technology?

Pressure-Enabled Drug Delivery (PEDD) is TriSalus’ proprietary approach designed to deliver more therapeutic agent directly to solid tumors while limiting exposure to normal tissue. It is used in FDA-cleared TriNav infusion systems and supports investigational immunotherapy delivery in the company’s regional immuno-oncology trials.

What is nelitolimod and how does it fit into TriSalus’ strategy?

Nelitolimod is TriSalus’ investigational immunotherapeutic, a class C Toll-like receptor 9 agonist. It is intended to counter the immunosuppressive tumor environment, particularly in liver and pancreatic cancers, and is being evaluated in Pressure-Enabled Regional Immuno-Oncology trials using the PEDD delivery platform.

Filing Exhibits & Attachments

5 documents

Press Releases

Other Documents